within Pharmacolibrary.Drugs.ATC.A;

model A10BD13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 18 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 12.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Metformin and alogliptin is a fixed-dose combination of two antihyperglycemic agents used in the treatment of type 2 diabetes mellitus. Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity, while alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion and decrease glucagon levels. This combination is approved for use in adults with type 2 diabetes mellitus when diet and exercise do not provide adequate glycemic control.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for usual adult population under typical dosing after oral administration; no published model specifically for the metformin and alogliptin combination, so parameters are based on combination of published values for individual components.</p><h4>References</h4><ol><li><p>Karim, A, et al., &amp; Mekki, Q (2010). Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. <i>International journal of clinical pharmacology and therapeutics</i> 48(1) 46–58. DOI:<a href=&quot;https://doi.org/10.5414/cpp48046&quot;>10.5414/cpp48046</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20040339/&quot;>https://pubmed.ncbi.nlm.nih.gov/20040339</a></p></li><li><p>Scott, LJ (2010). Alogliptin: a review of its use in the management of type 2 diabetes mellitus. <i>Drugs</i> 70(15) 2051–2072. DOI:<a href=&quot;https://doi.org/10.2165/11205080-000000000-00000&quot;>10.2165/11205080-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20883057/&quot;>https://pubmed.ncbi.nlm.nih.gov/20883057</a></p></li><li><p>Janardhan, S, &amp; Sastry, GN (2014). Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment. <i>Current drug targets</i> 15(6) 600–621. DOI:<a href=&quot;https://doi.org/10.2174/1389450115666140311102638&quot;>10.2174/1389450115666140311102638</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24611684/&quot;>https://pubmed.ncbi.nlm.nih.gov/24611684</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BD13;
